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The application of cytostatic drugs targeting the high proliferation rates of cancer cells is cur-
rently the most commonly used treatment option in cancer chemotherapy. However, severe
side effects and resistance mechanisms may occur as a result of such treatment, possibly
limiting the therapeutic efficacy of these agents. In recent years, several therapeutic strate-
gies have been developed that aim at targeting not the genomic integrity and replication
machinery of cancer cells but instead their protein homeostasis. During malignant transfor-
mation, the cancer cell proteome develops vast aberrations in the expression of mutated
proteins, oncoproteins, drug- and apoptosis-resistance proteins, etc. A complex network of
protein quality-control mechanisms, including chaperoning by heat shock proteins (HSPs),
not only is essential for maintaining the extravagant proteomic lifestyle of cancer cells but
also represents an ideal cancer-specific target to be tackled. Furthermore, the high rate of
protein synthesis and turnover in certain types of cancer cells can be specifically directed
by interfering with the proteasomal and autophagosomal protein recycling and degradation
machinery, as evidenced by the clinical application of proteasome inhibitors. Since proteins
with loss of their native conformation are prone to unspecific aggregations and have proved
to be detrimental to normal cellular function, specific induction of misfolded proteins by
HSP inhibitors, proteasome inhibitors, hyperthermia, or inducers of endoplasmic reticulum
stress represents a new method of cancer cell killing exploitable for therapeutic purposes.
This review describes drugs – approved, repurposed, or under investigation – that can be
used to accumulate misfolded proteins in cancer cells, and particularly focuses on the
molecular aspects that lead to the cytotoxicity of misfolded proteins in cancer cells.
Keywords: proteasome, autophagy, bortezomib, nelfinavir, endoplasmic reticulum stress, aggresome, HDAC6
INTRODUCTION: HOW DO PROTEINS FOLD ANDWHAT
MAKES MISFOLDED PROTEINS DANGEROUS?
For an understanding of misfolded proteins, it is necessary to
understand how cellular proteins attain and then further maintain
their native conformation and how mature proteins and unfolded
proteins are generated and converted into each other.
The principles and mechanisms of protein folding were one
of the major research topics and achievements of biochemical
research in the last century. For decades, Anfinsen’s model, which
explained protein structure by thermodynamic principles apply-
ing to the polypeptide’s inherent amino acid sequence (1), was to
be found in the introductory sections of all textbooks in protein
biochemistry. According to Anfinsen’s thermodynamic hypothe-
sis, the structure with the lowest conformational Gibbs free energy
was finally taken by each single polypeptide due to a thermo-
dynamic and stereochemical selection for side chain relations
that form most stable and effective enzymes or structural pro-
teins (1). Beyond this individual selection for the energetically
most optimized conformation, evolution also selected for amino
acid sequences that energetically allowed the smoothest and most
“frustration-free” folding processes via a thermodynamic “folding
funnel” (1–3).
Whereas Anfinsen’s model preferred the side chain elements
as preferential organizing structures, recent hypotheses have
inversely proposed the backbone hydrogen bonds as the driving
force behind protein folding (4). According to the former the-
ory, the finally folded protein was assumed to attain a single
defined structure and shape (1, 4), and the unfolded conditions
were described as being represented by a structureless statistical
coil with nearly indefinite conformations – a so-called “featureless
energy landscape” (4). The latter model assumes that a protein
selects during its folding process from a limited repertoire of sta-
ble scaffolds of backbone hydrogen bond-satisfied α-helices and
β-strands (4). This also implies that unfolded proteins are not
structureless, shoelace-like linear amino acid alignments as often
depicted in cartoons for graphical reasons, but actually, at least in
part, retain discrete and stable scaffolds.
Once the protein has attained its final conformation, the prob-
lem of stabilizing this structure arises. Hydrophobic interactions
that press non-polar side chains into the center of the protein are
assumed to be a major force in protein stabilization (5, 6). At the
protein surface, polar interactions, mainly by hydrogen bonds of
polar side chains and backbone structure, are assumed to be of
similar importance (6). Salt bridges and covalent disulfide bonds
were identified as further forces supporting the stability of proteins
(6). Accordingly, all conditions that interfere with these stabilizing
forces, including extreme temperature, salt concentrations, and
redox conditions, may lead to protein misfolding.
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Another aspect that must be taken into account when study-
ing protein folding relates to the very different conditions found
in viable cells when compared to test tube conditions. Consider-
ing the life-cycle of a protein, each protein begins as a growing
polypeptide chain protruding from the ribosomal exit tunnel and
with several of its future interacting amino acid binding partners
not even yet attached to the growing chain of the nascent polymer.
In these ribosomal exit tunnels, first molecular interactions and
helical structures are formed, and evidence exists to support the
notion that the speed of translation is regulated by slow translat-
ing codon sequences just to optimize these first folding processes
(7). After leaving the ribosomal tunnel, nascent polypeptides are
also directly welcomed by chaperoning protein complexes, which
facilitate and further guide the folding process of newly synthe-
sized proteins (8). It is believed that a high percentage of nascent
proteins are subject to immediate degradation due to early folding
errors (9). Since many nascent proteins are synthesized in paral-
lel at polysomes, the temporal and spatial proximity of unfolded
peptides brings the additional risk of protein aggregation (10).
Moreover, as mentioned above, even incomplete folding interme-
diates and partially folded states may form energetically but not
physiologically active metastable structures (11, 12). An immedi-
ate, perinatal guidance and chaperoning of newborn proteins is
therefore essential to creating functional, integrative proteins and
to avoiding misfolded, function-less polypeptides with potentially
cytotoxic features.
Since protein structure and function are coupled, misfolded
proteins are, at first, loss-of-function proteins that might reduce
cell viability, in particular when generated in larger quantities. A
more dangerous feature of misfolded proteins, however, lies in
their strong tendency toward abnormal protein–protein interac-
tions or aggregations, which is reflected by the involvement of
misfolded proteins and their aggregates in several amyloidotic dis-
eases, including neurodegenerative syndromes such as Alzheimer’s
disease and Parkinson’s disease (13, 14). The fact that several
of these intracellular and extracellular protein aggregates con-
tain β-sheet-like structures and form filamentous structures also
supports the notion that misfolded proteins are not necessarily
structureless protein coils or unspecific aggregates, at least when
they are formed by homogenous proteins as in the case of sev-
eral neurodegenerative diseases (13). Paradoxically, these larger
aggregates appear to reflect a cell protective mechanism so as to
sequester or segregate smaller, but highly reactive, nucleation cores
of condensing protein aggregates (13).
Unspecific hydrophobic interactions, in particular, have been
held responsible for protein aggregations that form when termi-
nally folded proteins lose their native conformation and expose
buried hydrophobic side chains on their surface (15, 16). These
hydrophobic interactions are also believed to be the most prob-
lematic issues with newly synthesized polypeptides on single
ribosomes or polysomes (12). Once exposed to the surface, the
hydrophobic structures will quickly find possible interaction part-
ners. The intracellular milieu can be regarded as a “crowded
environment” (17), fully packed with proteins in close contact and
near to their solubility limit (8, 12). Thus, misfolded proteins not
only aggregate among each other but may also attach to normal
native proteins and inhibit their function and activity. Since such
misfolding effects and interactions can also include nuclear DNA
replication and repair enzymes (18), misfolded proteins may not
only exert proteotoxic but also genotoxic effects, thereby endan-
gering the entire cellular “interactome” (19) by interfering both
with the integrity of the proteome (proteostasis) and the genome.
Therefore, a misfolded protein is not simply a loss-of-function
protein but also a promiscuous little villain that might act like a
free radical, exerting uncontrolled danger to the cell.
The way in which cells deal with misfolded proteins strongly
depends on the nature, strength, length, and location of the
damage induced by the various insults. Management of mis-
folded proteins can be achieved by heat shock protein (HSP)-
mediated protein renaturation (repair); proteasomal, lysosomal,
or autophagosomal degradation (recycling); intracellular disposal
(aggregation); or – in its last consequence if overwhelmed – by
programed cell death (despair). In the following paragraphs, the
cellular management of misfolded proteins is described and ther-
apeutic options to induce misfolded proteins in cancer cells are
presented.
Hsp90 AND Hsp90 INHIBITORS
The best-known and evolutionarily most-conserved mechanism
to protect against protein misfolding is the binding and refold-
ing process mediated by so-called heat shock proteins (HSPs).
HSPs recognize unfolded or misfolded proteins and facilitate their
restructuring in either an ATP-dependent (large HSPs) or energy-
independent manner (low weight HSPs). HSP of 90 kDa (hsp90)
is a constitutively expressed HSP and is regarded as the most com-
mon and abundantly expressed HSP in eukaryotic cells (20, 21).
Although commonly referred to as hsp90, it consists of a vari-
ety of isoforms that are encoding for cytosolic (hsp90α1, α2, β),
mitochondrial (TRAP1), or endoplasmic reticulum (ER)-resident
(GRP94) forms. Its primary function is less that of a stress response
protein and more to bind to a certain group of client proteins
unable to maintain a stable configuration without being assisted
by hsp90 (20, 22, 23). Steroid hormone receptors (estrogen recep-
tor, glucocorticoid receptor), cell cycle regulatory proteins (CDK4,
cyclin D, polo-like kinase), and growth factor receptors and their
downstream targets (epidermal growth factor receptor 1, HER2,
AKT) are among the best-studied client proteins of hsp90 (20–
22). Also, several cancer-specific mutations generating otherwise
instable oncoproteins, such as mutant p53 or bcr-abl, rely on hsp90
chaperoning to keep them in a soluble form, thereby facilitating the
extravagant but vulnerable“malignant lifestyle”of hsp90-addicted
cancer cells (21, 24). Accordingly, hsp90 has been assumed to
be a prominent target, in particular for hormone-responsive and
growth factor receptor amplification-dependent cancer types.
The microbial antibiotics geldanamycin and radicicol are the
prototypes of hsp90 inhibitors. Based on intolerable toxicity,
these molecules had to be chemically modified for application
in humans, and most of the ongoing clinical studies with hsp90
inhibitors are aimed at identifying semi-synthetic derivatives of
these lead compounds with an acceptable risk profile. Unfortu-
nately, most recent studies using geldanamycin derivatives have
provided disappointing results because of toxicities and insuffi-
cient efficacy (22, 25–27). Studies with radicicol (resorcinol) deriv-
atives, in particular with ganetespib, appear to be more promising
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because of fewer adverse effects (22, 25–27). Liver and ocular (reti-
nal) toxicities have been described as main adverse effects of hsp90
inhibition, and appeared to be experienced less with ganetespib
than with most of the first generation hsp90 inhibitors (28).
Since both geldanamycin and radicicol target the highly con-
served and unique ATP-binding domain of hsp90, new synthetic
inhibitors have also been generated by rational drug design (22,
25–27). However, none of the various natural or synthetic hsp90
inhibitors under investigation have yet provided convincing clini-
cal data, and future studies will show whether hsp90 can eventually
be added to the list of effective cancer targets.
Hsp70, Hsp40, Hsp27, AND HSF1
Hsp90 is assisted by several other HSPs and non-chaperoning co-
factors, finally forming a large protein complex that recruits and
releases client proteins in an energy-dependent manner (21, 22,
29). Client proteins for hsp90 are first bound to hsp70, which
transfers the prospective client to hsp90 through the mediating
help of an hsp70–hsp90 organizing protein (HOP). Binding of
potential hsp90 client proteins to hsp70 is facilitated by its co-
chaperone hsp40 (23, 30). Exposed hydrophobic amino acids, the
typical feature of misfolded proteins, have been described as the
main recognition signal for hsp70 proteins (15, 16, 31). Hsp70
proteins are not only supporter proteins for hsp90 but also rep-
resent a large chaperone family capable of acting independently
of hsp90 and that can be found in all cellular compartments,
including cytosol and nucleus (hsp70, hsp72, hsc70), mitochon-
dria (GRP75=mortalin), and the ER (GRP78=BiP). Hsp70
chaperones may act on misfolded or nascent proteins either as
“holders” or “folders” (31), which means that they prevent protein
aggregation either by sheltering these aggregation-prone protein
intermediates or by allowing these proteins to fold/refold into their
native form in an assisted mechanism within a protected environ-
ment (31). Hsc70 (HSPA8) is a constitutively expressed major
hsp70 isoform that is an essential factor for normal protein home-
ostasis even in unstressed cells (16). Misfolded proteins can also
be destined by hsp70 proteins for their ultimate degradation. Pro-
teins that expose KFERQ amino acid motifs on their surface during
their unfolding process are preferentially bound by hsc70 and can
be directed to lysosomes in a process called chaperone-mediated
autophagy (CMA) (32, 33). In another mechanism of targeted pro-
tein degradation, interaction of hsc70 with the E3 ubiquitin ligase
CHIP (carboxyl terminus of Hsc70-interacting protein) leads to
ubiquitination of misfolded proteins and thus their destination of
the ubiquitin-proteasome protein degradation pathway (34, 35).
Since hsc70 is essential for normal protein homeostasis and its
knock-out is lethal in mice (16, 36), hsc70 inhibition might not
be an optimal target for cancer-specific induction of misfolded
proteins. This contrasts with the inducible forms of hsp70 such
as hsp72 (HSPA1), which are upregulated in a cell stress-specific
manner and are often found to be constitutively overexpressed
in cancer tissues (16, 36). Transcriptional activation of these
inducible HSPs is mediated by the heat shock factor 1 (HSF1),
which also regulates expression of hsp40 and the small HSP hsp27
by sharing a common promoter consensus sequence (heat shock
response element) for HSF1 binding (37). HSF1 was also found
to be constitutively activated in cancer tissues, modulating several
cell cycle- and apoptosis-related pathways via its target genes (38–
40). HSF1 itself is kept inactive in the cytosol by binding to hsp90,
and the recruitment of hsp90 to misfolded proteins is consid-
ered a main activation mechanism to release monomeric HSF1
for its subsequent trimerization, post-translational activation, and
nuclear translocation (24, 41). Also, since hsp90 inhibition causes
hsp70 induction by HSF1 activation as a compensatory feed-back
mechanism (24), combined inhibition of hsp90 and hsp70, or of
hsp90 and HSF1 might be a more effective therapeutic approach
for cancer treatment than single HSP targeting alone.
Indeed, several small-molecule inhibitors and aptamers for
hsp70, hsp40, and hsp27 have been designed (16, 42–44), but
most of them remain in pre-clinical development, or are either not
applicable in humans or associated with intolerable side effects (16,
42–44). Notably, the natural bioflavonoid quercetin was shown to
inhibit phosphorylation and transcriptional activity of the heat
shock transcription factor HSF1, thus reducing HSP expression
at its most basal level (45–48). This HSP and HSF1 inhibition
may also contribute to the observed cancer-preventing effects of a
flavonoid-rich diet, which includes fruits and vegetables. However,
due to their low bioavailability, the concentrations of flavonoids
needed to induce direct cytotoxic effects in cancer cells for (chemo-
)therapeutic reasons are obviously not achievable in humans, even
when applied as nutritional supplements (49). More effective and
clinically more easily applicable inhibitors of HSF1 are therefore
urgently sought. Promising HSF1 targeting strategies are currently
under development, although are apparently not yet suited for
clinical applications (24, 50, 51).
PROTEIN UBIQUITINATION AND PROTEASOMAL
DEGRADATION
Ubiquitin is a 76 amino acid polypeptide that can covalently be
attached via its carboxy-terminus to free (lysyl) amino groups of
proteins. Ubiquitination of proteins generates a cellular recogni-
tion motif that is involved in various functions ranging from tran-
scription factor and protein kinase activation to DNA repair and
protein degradation – depending on the extent and exact location
of this post-translational modification (52, 53). Monoubiquitina-
tion of peptides of more than 20 amino acids was found to be a
minimal requirement for protein degradation, but the canonical
fourfold (poly-)ubiquitination with three further lysine (K48) side
chain-linked ubiquitins appears to be most apt for an effective and
rapid substrate recognition by the proteasome (54). This canonical
polyubiquitin structure, as well as several other mixed polyubiq-
uitin structures, can be recognized by the external 19S subunits
of the 26S proteasome complex (54, 55). Prior to degradation of
ubiquitinated proteins by the proteasomal 20S core subunit, the
attached ubiquitin chains are released by the external 19S subunits
for recycling, although they can also be co-degraded by the pro-
teasome (56). After first passing the 19S subunit, the proteasomal
target proteins are then unfolded in an energy-dependent manner
and introduced into the narrow enzymatic cavity of proteasome
for degradation. The barrel-shaped 20S proteasomal core com-
plex contains three different proteolytic activities in duplicate (β1:
caspase-like-, β2: tryptic-, and β5: chymotryptic activity), which
initiate an efficient cleavage of the proteasomal target proteins into
smaller peptides (57).
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It is important to note that specific ubiquitination and ensuing
proteasomal degradation is not an exclusive degradation mecha-
nism of misfolded proteins but is also used to regulate the expres-
sion level of several native cell cycle regulatory proteins [cyclins,
proliferating cell nuclear antigen (PCNA), p53], signaling pathway
molecules (β-catenin, IκB), and survival factors (mcl-1) during the
course of normal protein homeostasis and cell cycle progression
(53, 55, 57, 58). Moreover, proteasomes are involved in protein
maturation, including the processing and maturation of the NF-
κB transcription factor subunit p50 and the drug-resistant protein
MDR1 (57). Therefore, targeting proteasomal activity has not only
been of interest for the generation of misfolded, cytotoxic proteins
but also for interfering with the expression of proteins involved in
several hallmarks of cancer, including cell cycle progression, signal
transduction, and apoptosis.
PROTEASOME INHIBITORS
Bortezomib (PS-341,Velcade ™) has long been known as a paragon
of a clinically applicable proteasome inhibitor. Bortezomib has
been approved for the treatment of multiple myeloma and mantle
cell lymphoma (55, 59, 60). The great expectations of transferring
the success of bortezomib to non-hematological solid cancer types
have unfortunately not yet been fulfilled. It has been suggested that
the high antibody-producing capacity of myeloma cells and thus
the need for an efficient proteasomal degradation system to cope
with the recycling process of misfolded ER-generated antibod-
ies [ER-associated degradation process (ERAD); see below] might
contribute to the high sensitivity of myeloma cells to bortezomib
(9, 60, 61). Originally, bortezomib was developed to inhibit the
proteasomal degradation of the NF-κB inhibitor IκB, thus tar-
geting the pro-inflammatory, but also cancer-promoting, effect
of the NF-κB transcription factor (55, 60, 62). Recent insights
indicate that the anti-tumoral effect of bortezomib is not only
mediated by its NF-κB inhibitory activity but also by its ability
to induce accumulation of misfolded proteins in the cytosol and
the ER (60, 62–65). However, the use of bortezomib, even for
highly sensitive multiple myeloma, is limited by its strong ten-
dency to induce a proteasome inhibition-independent peripheral
neuropathy by acting on neuronal mitochondria (61). Since neu-
rodegenerative diseases are associated with protein misfolding and
aggregation, the neuropathological effects of bortezomib might
also be assumed to be mediated by the possible proteotoxic effects
of bortezomib in neuronal cells. However, although proteasome
inhibitor-induced neurodegeneration and inclusion body forma-
tion have been described in animal models, similarities between
proteasome inhibitor-induced neurodegeneration and Parkinson’s
disease-like histopathological features could not be established
(66).
Due to the neurotoxic side effects of bortezomib and an increas-
ing occurrence of refractory myelomas, much effort has been made
to generate and identify new proteasome inhibitors with fewer
adverse effects. In 2012, the irreversible proteasome inhibitor and
epoxomicin derivate carfilzomib (Kyprolis™) was approved for
treatment of bortezomib-resistant and relapsed multiple myeloma
patients (62, 67). Although sharing the same target with borte-
zomib, the chymotryptic activity of the proteasome, carfilzomib
was shown to overcome bortezomib resistance and to be associated
with fewer neuropathological adverse effects than bortezomib (62,
67, 68) (Table 1). Since carfilzomib has the advantage of being an
irreversible proteasome inhibitor, a more patient-friendly admin-
istration schedule with less frequent application and a better
compliance may add to the advantages of carfilzomib.
Additional newly generated proteasome inhibitors have been
developed, which are currently being tested in clinical trials (53,
61, 65, 69) and will hopefully soon expand our limited arse-
nal of clinically applicable proteasome inhibitors. Unfortunately,
both bortezomib and carfilzomib are extremely expensive medica-
tions and result in high therapy costs (68), so more cost-effective
proteasome inhibitors are urgently needed. Interestingly, several
natural polyphenols have been described as exerting proteasome-
inhibitory activity (70, 71). As mentioned, however, the clinical
use of flavonoids in cancer treatment is limited due to their poor
bioavailability (49, 72), although the compounds may be used
as lead molecules for the development of proteasome inhibitors.
Notably, natural flavonoids have also been identified as reducing
the therapeutic efficacy of bortezomib by a direct chemical interac-
tion of vicinal hydroxyl groups of flavonoids with the boronic acid
residue of bortezomib, thus leading to disregard of a combination
therapy of bortezomib with flavonoids (73).
Instead, other combination therapies of bortezomib, in par-
ticular with hsp90 inhibitors appear to be more appropriate for
therapeutic applications. A clinical study with the geldanamycin-
derivate 17-AAG and bortezomib, however, revealed no clinical
response but severe adverse effects resulted from this combina-
tion in acute myeloid leukemia patients (74). By contrast, a study
with bortezomib and the hsp90 inhibitor tanespimycin in patients
with relapsed and refractory multiple myeloma (75) revealed an
objective response rate of 27% and was described to be well tol-
erated (75). In patients with diverse solid cancer receiving similar
doses of this drug combination, however, no objective response
was observed (76).
DISULFIRAM
Another prospective tool for cost-effective proteasome inhibi-
tion is the repurposed use of approved and (if ever possible)
patent-free drugs that have also proved to cause proteasome inhi-
bition as an off-target effect. The alcohol-deterring drug disulfiram
(Antabuse) has been shown to be a highly active proteasome
inhibitor (77, 78), in particular when combined with endogenous
or exogenous copper ions (79). Treatment of cancer cells with
disulfiram caused all characteristics of efficient proteasome inhi-
bition, including NF-κB inhibition and accumulation of polyu-
biquitinated proteins and protein aggregates (77, 78, 80). Notably,
non-malignant cells responded less to disulfiram treatment, in
accordance with the low toxicity profile of this well-tolerated drug,
as also experienced in course of its use for anti-alcoholism for over
60 years (79). In addition to its proteasome-inhibitory effect, disul-
firam/copper has been shown to generate reactive oxygen species
in cancer cells, further contributing to the large amount of mis-
folded and aggregated proteins seen after disulfiram treatment (78,
80). Disulfiram is degraded in vivo into various reactive metabo-
lites, one of which, diethyldithiocarbonate, is able to covalently
bind to reactive thiol groups of proteins and to inactivate cancer-
promoting kinases and drug-resistance-conferring enzymes such
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Table 1 | Drugs described in this review and their mechanism of action (MOA), status of approval, and main adverse effects.
Drug MOA Clinical application Main adverse effects
Bortezomib
(VelcadeTM)
Proteasome inhibitor Approval: multiple myeloma (MM); mantle cell lymphoma Neutropenia and peripheral neuropathy (may
lead to treatment abrogation)Trials: lung cancer; breast cancer; ovarian cancer; cervical
cancer; prostate cancer; melanoma; colorectal cancer;
pancreatic cancer; renal cancer; brain cancer; thyroid cancer;
liver cancer; and diverse other solid cancers
Carfilzomib
(KyprolisTM)
Proteasome inhibitor Approval: refractory, bortezomib-resistant MM Cardiotoxicity; pulmonary hypertension/lung
problems; hepatic and renal toxicity; anemia.
No pronounced neurotoxic effects.
Trials: MM; lymphoma; unspecified solid cancers
Nelfinavir
(ViraceptTM)
ER stress inducer;
ROS generator
Approval: HIV infection Gastrointestinal adverse effects; lipid
metabolism disturbance; and insulin
resistance (long-term)
Trials: lung cancer; pancreatic cancer; cervical cancer; renal
cancer; glioblastoma; colorectal cancer; MM
Disulfiram
(AntabuseTM)
Proteasome inhibitor;
ROS generator
Approval: alcohol abuse Alcohol intolerance; mild gastrointestinal,
dermatologic, and ocular side effects. May
affect nervous system.
Trials: melanoma; breast cancer; liver cancer; glioblastoma;
prostate cancer
Ganetespib HSP90 inhibitor Trials: lung cancer; breast cancer; colorectal cancer; ovarian
cancer; prostate cancer; liver cancer; melanoma; AML; MM
Neutropenia; nausea; fatigue; diarrhea
Ricolinostat
(ACY-1215)
HDAC6 inhibitor Trials: MM; lymphoma Neutropenia
Chloroquine Autophagy inhibitor Approval: malaria treatment and prophylaxis; arthritis Gastrointestinal and visual problems; renal
and cardiac toxicity; pruritusTrials: lung cancer; breast cancer; glioblastoma; MM
MM, multiple myeloma; AML, acute myeloid leukemia; ROS, reactive oxygen species.
as protein kinase C (PK-C), P-glycoprotein (MDR1), DNA methyl-
transferases (DNMT), and aldehyde dehydrogenase (ALDH) (81).
Inhibition of ALDH has long been held responsible for the alcohol-
deterring effect of disulfiram, but ALDH is also known to belong
to a group of cancer-related genes referred to as cancer stem cell
genes (81). Since cancer stem cell genes have been held responsi-
ble for drug resistance and cancer recurrence, targeting of ALDH1
by disulfiram may also tackle the highly drug-resistant cancer
stem cell subpopulation. These promising pleiotropic, but mostly
cancer cell specific, proteotoxic effects of disulfiram recently insti-
gated several clinical trials with disulfiram in cancer patients
(79, 82).
AGGRESOME FORMATION AND RE-SOLUBILIZATION: ROLE
OF HDAC6
As depicted above, proteasome and HSP inhibition will eventu-
ally lead to the accumulation of misfolded and polyubiquitinated
proteins. Based on their inherent cohesive properties mediated
by their exposed hydrophobic surfaces, both ubiquitinated and
non-ubiquitinated misfolded proteins tend to adhere as small
aggregates (Figure 1). Individual ubiquitinated proteins and small
ubiquitinated aggregates can be recognized by specific ubiquitin-
binding proteins such as HDAC6 via its zinc finger ubiquitin-
binding domain. HDAC6 is an unusual histone deacetylase located
in the cytosol that regulates microtubule acetylation and is also
able to bind ubiquitinated proteins. Based on HDAC6’s additional
ability to bind to microtubule motor protein dynein, these aggre-
gates are actively transported along the microtubular system into
perinuclear aggregates around the microtubule organizing center
(MTOC) (10, 83, 84). Recognition of small, scattered ubiquiti-
nated aggregates by HDAC6 has been described as being medi-
ated by unanchored ubiquitin chains, which are generated by
aggregate-attached ubiquitin ligase ataxin-3 (85). Whereas pro-
teasomal target proteins are primarily tagged by K-48 (lysine-48)
linked ubiquitins; K-63 linked ubiquitin chains appear to be a
preferential modification for aggresomal targeting by HDAC6 and
were assumed to mediate a redirection from proteasomal degrada-
tion to aggresome formation in the case of proteasomal inhibition
or overload (86). Accordingly, aggresome formation is not an
unspecific protein aggregation but a specific, ubiquitin-controlled
sorting process. Furthermore, these aggresomes consist not only
of misfolded and deposited proteins but have also been shown to
contain a large amount of associated HSPs and ubiquitin-binding
proteins, including HDAC6 [Figure 1; (10, 83, 84)]. Aggresomes
contain, and are also surrounded by, large numbers of proteasomes
(10, 83, 84), which help to resolubilize these aggregates not only
through their intrinsic proteasomal digestion but also by generat-
ing unanchored K63-branched polyubiquitin chains, which then
stimulate HDAC6-mediated autophagy, another cellular disposal
mechanism in involving HDAC6 (87). Notably, HDAC6 has also
been shown to control further maturation of autophagic vesi-
cles by stimulating autophagosome–lysosome fusion (Figure 1)
in a manner different from the normal autophagosome–lysosome
fusion process (88).
The HDAC6 multitalent also exerts its deacetylase activity
on hsp90 and modifies hsp90 client binding by facilitating its
chaperoning of steroid hormone receptors and HSF1 (89–91).
Recruitment of HDAC6 to ubiquitinated proteins leads to the
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FIGURE 1 | Drugs that inhibit folding or disposal of misfolded
proteins. Native mature proteins, nascent proteins, or misfolded proteins
can be prevented from folding or refolding by small and large heat shock
protein inhibitors, of which the hsp90 inhibitors based on geldanamycin
and radicicol are currently the most advanced in clinical studies. To avoid
accumulation of misfolded proteins, their degradation can be mediated by
hsc70, which may divert these proteins either to lysosomes to be
degraded by chaperone-mediated autophagy or, by specific ubiquitination,
to proteasomes. In case of unmanageable amounts of misfolded proteins
or proteasome inhibition, unspecific aggregation of these proteins may
occur. These highly cytotoxic small protein aggregates can be sequestered
in an HDAC6-dependent manner with the help of microtubules into large,
perinuclear aggresomes near the microtubule organizing center. Inhibition
of HDAC6 by tubacin, tubastatin, or ACY-1215 inhibits disposal of
microaggregates and may enhance the toxicity of bortezomib and HSP
inhibitors. Aggresomes are not final deposits but may be re-dissolved
either en bloc by macroautophagy or by molecular segregation via
p97/VCP and final degradation by proteasomes. The p97/VCP inhibitor
eeyarestatin may inhibit this degradation pathway but also aggresome
formation by interfering with ataxin-3. Eeyarestatin also inhibits both
anterograde and retrograde transport of ER proteins. Induction of ER
stress induces the unfolded protein response by sequestering BiP from
membrane receptors ATF6, PERK, and IRE. The unfolded protein response
leads to cytoprotective chaperone synthesis but also to the expression of
pro-apoptotic CHOP, NOXA, and c-JUN-kinase activation in case of
prolonged or unmanageable ER stress. ER stress may also be alleviated by
autophagy, whose efficacy can be inhibited by the lysosomotropic
anti-malaria drug chloroquine.
dissociation of the repressive HDAC6/hsp90/HSF1 complex (91)
and allows the release of transcriptionally active HSF1 to the
nucleus. The engagement of HDAC6 at the aggresome–autophagy
pathway hence also indirectly facilitates HSF1 activity. p97/VCP
(valosin-containing protein), another binding partner of HDAC6
and itself a multi-interactive, ATP-dependent chaperone (92–94),
is assumed to be involved not only in the specific separation of
hsp90 and HSF1 by its “segregase” activity but also in the binding
and remodeling of polyubiquitinated proteins before their deliv-
ery to the proteasome (93–95). Additionally, p97/VCP dissociates
polyubiquitinated proteins bound to HDAC6 (91). Accumulation
of polyubiquitinated proteins thus leads to HDAC6-dependent
HSF1 activation and HSP induction, p97/VCP-dependent recruit-
ment and “preparation” of polyubiquitinated proteins to protea-
somes, and, in the case of pharmacological proteasome inhibition
or physiological overload, to an HDAC6-dependent detoxifica-
tion of polyubiquitinated proteins by the aggresome/autophagy
pathway.
PHARMACOLOGICAL INHIBITION OF AGGRESOME
FORMATION: HDAC6 INHIBITORS
The central involvement of HDAC6 in aggresome formation and
clearance makes HDAC6 one of the most interesting druggable
targets for the induction of proteotoxicity in cancer cells. Also,
HDAC6 has been found to be overexpressed in various can-
cer tissues, associated with advanced cancer stages and increased
neoplastic transformation (96). Several pan-histone deacetylase
inhibitors have been developed and tested in clinical studies for
a variety of diseases, including different types of cancer (97, 98).
Although hematological malignancies responded best to most of
the already clinically tested pan-histone deacetylase inhibitors,
the efficacy on solid cancer types was disappointingly poor and
also associated with intolerable side effects (98). The unfore-
seeable pleiotropic epigenetic mechanism caused by non-specific
(nuclear) histone deacetylase inhibitors may also limit their appli-
cation for use in cancer treatment or HDAC6 inhibition, and has
led to the search for selective HDAC6 inhibitors with no inhibitory
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effects on transcription modifying histone deacetylases. Through
screening of small molecules under the rationale of selecting
for tubulin deacetylase inhibitors with no cross-reactive histone
deacetylase activity, the HDAC6 inhibitor tubacin was identified,
and suggested for use in the treatment of neurodegenerative dis-
eases or to reduce cancer cell migration and angiogenesis (99).
Hideshima et al. then proved the hypothesis that the combined
use of bortezomib with tubacin leads to an accumulation of non-
disposed cytotoxic proteins and aggregates in cancer cells (100).
Indeed, a synergistic effect of these two drugs against multiple
myeloma cells could be observed with no detectable toxic effect
on peripheral blood mononuclear cells (100). This and follow-
up studies also revealed the efficacy of tubacin as a single agent
against leukemia cells (100, 101) and a chemo-sensitizing effect on
cytotoxic drugs in breast- and prostate-cancer cells (102).
Another specific HDAC6 inhibitor, tubastatin A (103) revealed
promising effects in neurodegenerative diseases (104) but dis-
played apparently limited efficacy on solid cancer cells (105). A
very interesting new and orally applicable HDAC6 inhibitor, ACY-
1215 (ricolinostat), has recently been developed, which causes ER
stress and caspase-dependent apoptosis in synergy with borte-
zomib in multiple myeloma cells (106). The promising pre-clinical
data and the oral applicability have instigated several clinical stud-
ies to test the efficacy of ACY-1215 either as a single agent or in
combination with bortezomib in patients with multiple myeloma
and other lymphoid malignancies1.
ENDOPLASMIC RETICULUM STRESS
Besides the cytosol, the ER is a major site for protein synthesis, in
particular for those proteins destined for extracellular secretion,
the cell membrane, or their retention within the endomembrane
system. At the rough ER, nascent proteins are co-translationally
transported across the ER membrane into the ER lumen (107),
where they immediately encounter ER-resident chaperones, most
prominently represented by hsp70 family member BiP/GRP78
and hsp90 family member GRP94 to help proper protein folding
(15, 108). Most of these proteins also undergo post-translational
modifications, including N- or O-linked glycosylation or pro-
tein disulfide bridge-building (109, 110), thereby adding further
mechanisms of protein stabilization but also challenges for proper
protein folding.
Similar to the situation in cytosolic protein biosynthesis, a large
proportion of nascent proteins in the ER are assumed to misfold
and to go “off-pathway” even under normal physiological condi-
tions. Furthermore, the ER lumen, narrowly sandwiched between
two phospholipid membranes, has been described as an even more
densely crowded environment than the cytosol, additionally facili-
tating unspecific protein attachments and aggregations (15). Since,
with the exception of bulk reticulophagy, the lumen of the ER con-
tains no endogenous protein degradation system, and the antero-
grade transport of ER proteins to the Golgi, lysosomes, endosomes,
or the extracellular environment requires properly folded proteins,
a retrograde transport of ER proteins into the cytosol remains the
only possible mechanism of preventing misfolded protein accu-
mulation within the ER. In this ERAD, misfolded proteins are
1http://www.clinicaltrials.com
re-exported across the ER membrane by a specific multi protein
complex, ubiquitinated by ER membrane-integrated ubiquitin
ligases, and finally become degraded by cytosolic proteasomes
(111, 112). Notably, association of the cytosolic p97/VCP pro-
tein, an important interacting partner with HDAC6, has also been
described as being an essential factor for driving the luminal pro-
teins through the ER membrane pore complex into the cytosol
(92, 112).
Accordingly, all agents and conditions that interfere with these
folding, maturation, and retranslocation processes can lead to pro-
tein misfolding and aggregation within this sensitive organelle.
Chemicals that act as glycosylation inhibitors (tunicamycin), cal-
cium ionophore inhibitors (A23187, thapsigargin), heavy metal
ions (cadmium, lead), reducing agents (dithiothreitol), as well
as conditions like hypoxia or oxidative stress, all lead to a phe-
nomenon called ER stress (113–116). In the ER-stress response,
a triad of ER membrane-resident signaling receptors and trans-
ducers, IRE1, ATF6, and PERK1, become activated and lead to
the transcriptional activation of cytosolic and ER-resident chap-
erones to cope with the increasing number of misfolded proteins.
Induction of autophagy (reticulophagy; ER-phagy) may also occur
and supports the removal of damaged regions of the ER (117).
Under very intensive or even unmanageable ER-stress conditions, a
variety of pro-apoptotic pathways ensue, including CHOP induc-
tion, c-JUN-kinase activation, and caspase cleavage (118–120),
which eventually prevails over the cytoprotective arm of the ER-
stress response and may lead to apoptosis. Targeting of protein
folding within the ER is therefore a very promising strategy to
induce apoptosis in cancer cells, in particular in those cancer
cells characterized by an unphysiologically high protein secretion
rate, such as, for example, multiple myeloma cells. Whereas the
above-mentioned drugs such as tunicamycin or thapsigargin are
valuable tools for cell biology studies, they display unacceptable
toxicities in humans and are not suited for therapeutic appli-
cations. Interestingly, several already established drugs used for
non-cancerous diseases have been described as inducing ER stress
at pharmacologically relevant concentrations in humans as an
off-target effect (113, 116). The non-steroidal anti-inflammatory
COX-2 inhibitor celecoxib is an approved drug to treat vari-
ous forms of arthritis and pain, but has also been described as
exerting ER stress by functioning as a SERCA (sarco/ER Ca2+
ATPase) inhibitor (113, 116). However, although well tolerated in
humans, the ER-stress-inducing ability of celecoxib seems to be
weaker than that of direct SERCA inhibitors such as thapsigar-
gin, and the usefulness of celecoxib against advanced cancer has
been questioned (116). Various HIV protease inhibitors have been
described as inducing ER stress in human tissue cells as a side effect
(121–123). In particular the HIV drugs lopinavir, saquinavir, and
nelfinavir appear to be potent inducers of the ER-stress reaction,
leading to a focused interest in these drugs for the induction of
ER stress and apoptosis in cancer cells (116, 124–128). In fact,
with currently over 27 clinical studies in cancer patients2, nel-
finavir, either used as a single agent or in combination therapy,
is on the list of the most promising prospective candidates to
induce selective proteotoxicity in cancer cells at pharmacologically
2www.clinicaltrials.gov
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relevant concentrations. Although the exact mechanism by which
nelfinavir induces ER stress is not yet clear, it was shown that
nelfinavir causes the upregulation of cytosolic and ER-resident
HSPs, and induces apoptosis in cancer cells associated with cas-
pase activation and induction of the pro-apoptotic transcription
factor CHOP (125, 126). Nelfinavir was also shown to be com-
binable with bortezomib to enhance its activity on cancer cells
(129). Since the retrograde transport of misfolded ER proteins
is inhibited by the p97/VCP inhibitor eeyarestatin (130, 131),
we recently tested the combination of eeyarestatin with nelfi-
navir but found no synergistic effect between these two agents in
cervical cancer cells (132). In contrast, eeyarestatin markedly sen-
sitized cervical cancer cells to bortezomib treatment (132), which
was also observed in preceding studies in which eeyarestatin was
used to augment the ER-stress-inducing ability of bortezomib
in leukemia cells (131). The combination of bortezomib with
eeyarestatin massively increased the accumulation of polyubiq-
uitinated proteins in cancer cells, induced macroautophagy, and
activated the pro-apoptotic ATF4/CHOP/NOXA-mediated path-
way of the ER-stress response (131, 132). These cytotoxic effects
were also observed when eeyarestatin was applied as a single agent
to cancer cells (131, 132), but not in normal blood cells (131).
Eeyarestatin as a single agent might therefore be of interest as
an alternative to bortezomib treatment, and has also success-
fully been applied in a xenograft model (133), although little is
known of its pharmacological effects in humans. In combination
with bortezomib, eeyarestatin might help to reduce the amount
of bortezomib needed to induce cytotoxic effects in solid cancer
cells (132).
THERAPEUTIC HYPERTHERMIA
Heat application is the most direct method to generate misfolded
proteins in cancer cells. Indeed, local, regional, and whole body
hyperthermia is a practiced cancer treatment modality, although in
most cases is used to support and improve the efficacy of radiother-
apy and chemotherapy (134, 135). Thanks to the basic or inducible
expression of HSPs, normal body cells, and cancer cells can with-
stand temperatures well above the core body temperature of 37°C.
In the oncologically relevant therapeutic temperature range of 40–
47°C, a time and temperature relation exists that defines whether
cells will survive or undergo cell death after heat exposure (136,
137). Temperatures between 40.5 and 42°C were described to cause
only weak heat stress and no extensive apoptosis in cancer cells,
with the extent of apoptosis rapidly increasing when temperatures
were elevated from 42 to 45°C (137, 138). Further temperature
elevation to 46–47°C then mainly causes unspecific, heat-induced
necrosis alone (138). Interestingly, at these elevated temperatures,
the quantity of HSPs is not further increased but instead decreased
(135). Instead, some HSPs, in particular hsp70, are translocated to
the cell membrane or are released by necrotic cells into the extracel-
lular milieu and are able to elicit an immunologic response against
surviving cancer cells (135, 139). The cellular response to heat is
also highly variable among cell types. Temperatures of more than
48–50°C are believed to be generally intolerable to cancer as well
as healthy body cells and can be used for local thermal ablation
(137) in cases where surgery is either not possible or not wanted
by the patient.
Although the whole cell and all its organelles are subjected to
the detrimental heat impact, the nucleus seems to be one of the
organelles most affected by hyperthermia. Non-histone nuclear
proteins appear to be particularly sensitive to heat inactivation,
resulting in denaturation of these nuclear proteins and their aggre-
gation among each other, but also to correctly folded, aggregation-
sensitive native proteins within the nucleus (18). Overall, this may
lead to nuclear enzyme inactivation, DNA masking by aggregated
proteins, impairment of DNA synthesis and repair, and a mitotic
catastrophe in case cells continue to divide (18, 136, 137). In addi-
tion to an additive pro-apoptotic effect of heat to the cytotoxic
insults of radiation or chemotherapeutic drugs on cancer cells
(136), the supportive effect of hyperthermia is probably also due
to the inhibitory effect of heat on DNA repair and drug detox-
ifying enzymes. However, despite several precious and specific
anti-cancer effects, hyperthermia, as mentioned above, has not
been established as a single cancer treatment but is primarily
used as a supportive modality in conjunction with chemo- and
radiotherapy (134, 135).
CONCLUSION AND PERSPECTIVES
Induction of proteotoxicity through the accumulation of mis-
folded proteins has evolved as a new treatment modality in the
fight against cancer. Clinically approved drugs such as borte-
zomib and carfilzomib provide evidence of the functionality of
this approach. Newly developed agents like the HDAC6 inhibitor
ACY-1215 or repurposed drugs like nelfinavir or disulfiram are
currently being tested in clinical trials with cancer patients and
will hopefully further broaden our arsenal of anti-cancer drugs.
Notably, most proteotoxic agents that have been approved or are
in clinical trials target the ubiquitin-proteasome-system (UPS)
and are mainly effective in multiple myeloma cells, which rely
on a functional ER/ERAD/UPS for excessive and proper antibody
production. Similarly, it can be assumed that other cancer cell
types with a marked secretory phenotype may also be affected by
ER/ERAD/UPS inhibitors. In accordance with this notion, a recent
dose-escalating Phase Ia study with nelfinavir as a single agent, that
covered a large variety of solid cancer entities, revealed response
rates primarily in patients with neuroendocrine tumors (140). In
most other solid cancer types, however, the chemo-sensitizing or
combination effects of proteotoxic drugs may prevail, and have
become the focus of an increasing number of very promising
clinical and pre-clinical studies.
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